Gastrointestinal drugs developer Relypsa has promoted Scott Garland to the position of president. Garland had previously served as senior vice president and chief commercial officer of the Redwood City, Calif-based company. Before joining Relypsa, Garland was vice president and chief commercial officer of South San Francisco-based Exelixis (NASDAQ: EXEL). His career also includes posts at Genentech and Amgen (NASDAQ: AMGN).
John Orwin, who is currently Relypsa’s president and CEO, will continue in his position until June 30. After that date, he will move into an advisory role with Vifor Pharma, Relypsa’s Switzerland-based parent company.